Alzheimers Disease-Pipeline Review, H2 2016

Alzheimers Disease-Pipeline Review, H2 2016


  • Products Id :- GMDHC8356IDB
  • |
  • Pages: 1284
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Alzheimer's Disease-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Alzheimer's Disease-Pipeline Review, H2 2016', provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease

The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects

The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 12

Alzheimer's Disease Overview 13

Therapeutics Development 14

Alzheimer's Disease-Therapeutics under Development by Companies 16

Alzheimer's Disease-Therapeutics under Investigation by Universities/Institutes 37

Alzheimer's Disease-Pipeline Products Glance 44

Alzheimer's Disease-Products under Development by Companies 48

Alzheimer's Disease-Products under Investigation by Universities/Institutes 78

Alzheimer's Disease-Companies Involved in Therapeutics Development 88

Alzheimer's Disease-Therapeutics Assessment 316

Drug Profiles 372

Alzheimer's Disease-Dormant Projects 1152

Alzheimer's Disease-Discontinued Products 1199

Alzheimer's Disease-Product Development Milestones 1209

Appendix 1221

List of Tables

Number of Products under Development for Alzheimer's Disease, H2 2016 76

Number of Products under Development for Alzheimer's Disease-Comparative Analysis, H2 2016 77

Number of Products under Development by Companies, H2 2016 79

Number of Products under Development by Companies, H2 2016 (Contd..1) 80

Number of Products under Development by Companies, H2 2016 (Contd..2) 81

Number of Products under Development by Companies, H2 2016 (Contd..3) 82

Number of Products under Development by Companies, H2 2016 (Contd..4) 83

Number of Products under Development by Companies, H2 2016 (Contd..5) 84

Number of Products under Development by Companies, H2 2016 (Contd..6) 85

Number of Products under Development by Companies, H2 2016 (Contd..7) 86

Number of Products under Development by Companies, H2 2016 (Contd..8) 87

Number of Products under Development by Companies, H2 2016 (Contd..9) 88

Number of Products under Development by Companies, H2 2016 (Contd..10) 89

Number of Products under Development by Companies, H2 2016 (Contd..11) 90

Number of Products under Development by Companies, H2 2016 (Contd..12) 91

Number of Products under Development by Companies, H2 2016 (Contd..13) 92

Number of Products under Development by Companies, H2 2016 (Contd..14) 93

Number of Products under Development by Companies, H2 2016 (Contd..15) 94

Number of Products under Development by Companies, H2 2016 (Contd..16) 95

Number of Products under Development by Companies, H2 2016 (Contd..17) 96

Number of Products under Development by Companies, H2 2016 (Contd..18) 97

Number of Products under Development by Companies, H2 2016 (Contd..19) 98

Number of Products under Investigation by Universities/Institutes, H2 2016 99

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 100

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 101

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 102

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 103

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 104

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 105

Comparative Analysis by Late Stage Development, H2 2016 106

Comparative Analysis by Clinical Stage Development, H2 2016 107

Comparative Analysis by Early Stage Development, H2 2016 108

Comparative Analysis by Unknown Stage Development, H2 2016 109

Products under Development by Companies, H2 2016 110

Products under Development by Companies, H2 2016 (Contd..1) 111

Products under Development by Companies, H2 2016 (Contd..2) 112

Products under Development by Companies, H2 2016 (Contd..3) 113

Products under Development by Companies, H2 2016 (Contd..4) 114

Products under Development by Companies, H2 2016 (Contd..5) 115

Products under Development by Companies, H2 2016 (Contd..6) 116

Products under Development by Companies, H2 2016 (Contd..7) 117

Products under Development by Companies, H2 2016 (Contd..8) 118

Products under Development by Companies, H2 2016 (Contd..9) 119

Products under Development by Companies, H2 2016 (Contd..10) 120

Products under Development by Companies, H2 2016 (Contd..11) 121

Products under Development by Companies, H2 2016 (Contd..12) 122

Products under Development by Companies, H2 2016 (Contd..13) 123

Products under Development by Companies, H2 2016 (Contd..14) 124

Products under Development by Companies, H2 2016 (Contd..15) 125

Products under Development by Companies, H2 2016 (Contd..16) 126

Products under Development by Companies, H2 2016 (Contd..17) 127

Products under Development by Companies, H2 2016 (Contd..18) 128

Products under Development by Companies, H2 2016 (Contd..19) 129

Products under Development by Companies, H2 2016 (Contd..20) 130

Products under Development by Companies, H2 2016 (Contd..21) 131

Products under Development by Companies, H2 2016 (Contd..22) 132

Products under Development by Companies, H2 2016 (Contd..23) 133

Products under Development by Companies, H2 2016 (Contd..24) 134

Products under Development by Companies, H2 2016 (Contd..25) 135

Products under Development by Companies, H2 2016 (Contd..26) 136

Products under Development by Companies, H2 2016 (Contd..27) 137

Products under Development by Companies, H2 2016 (Contd..28) 138

Products under Development by Companies, H2 2016 (Contd..29) 139

Products under Investigation by Universities/Institutes, H2 2016 140

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 141

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 142

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 143

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 144

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 145

Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 146

Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 147

Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 148

Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 149

Alzheimer's Disease-Pipeline by AB Science SA, H2 2016 150

Alzheimer's Disease-Pipeline by AbbVie Inc, H2 2016 151

Alzheimer's Disease-Pipeline by AC Immune SA, H2 2016 152

Alzheimer's Disease-Pipeline by Accera, Inc., H2 2016 153

Alzheimer's Disease-Pipeline by Acelot, Inc., H2 2016 154

Alzheimer's Disease-Pipeline by Actinogen Limited, H2 2016 155

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals, Inc., H2 2016 156

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, H2 2016 157

Alzheimer's Disease-Pipeline by Affibody AB, H2 2016 158

Alzheimer's Disease-Pipeline by AFFiRiS AG, H2 2016 159

Alzheimer's Disease-Pipeline by Alector LLC, H2 2016 160

Alzheimer's Disease-Pipeline by Alkermes Plc, H2 2016 161

Alzheimer's Disease-Pipeline by Allergan Plc, H2 2016 162

Alzheimer's Disease-Pipeline by Allinky Biopharma, H2 2016 163

Alzheimer's Disease-Pipeline by ALSP, Inc., H2 2016 164

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, H2 2016 165

Alzheimer's Disease-Pipeline by Alzinova AB, H2 2016 166

Alzheimer's Disease-Pipeline by AlzProtect SAS, H2 2016 167

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 168

Alzheimer's Disease-Pipeline by Amgen Inc., H2 2016 169

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp., H2 2016 170

Alzheimer's Disease-Pipeline by Aphios Corporation, H2 2016 171

Alzheimer's Disease-Pipeline by Apodemus AB, H2 2016 172

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences, S.L., H2 2016 173

Alzheimer's Disease-Pipeline by Araclon Biotech, S.L., H2 2016 174

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals, Inc., H2 2016 175

Alzheimer's Disease-Pipeline by ArmaGen Inc., H2 2016 176

Alzheimer's Disease-Pipeline by Artery Therapeutics, Inc., H2 2016 177

Alzheimer's Disease-Pipeline by AskAt Inc., H2 2016 178

Alzheimer's Disease-Pipeline by Astellas Pharma Inc., H2 2016 179

Alzheimer's Disease-Pipeline by AstraZeneca Plc, H2 2016 180

Alzheimer's Disease-Pipeline by Asubio Pharma Co., Ltd., H2 2016 181

Alzheimer's Disease-Pipeline by Ausio Pharmaceuticals, LLC, H2 2016 182

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 183

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, H2 2016 184

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd., H2 2016 185

Alzheimer's Disease-Pipeline by Axsome Therapeutics, Inc., H2 2016 186

Alzheimer's Disease-Pipeline by Axxam SpA, H2 2016 187

Alzheimer's Disease-Pipeline by Beactica AB, H2 2016 188

Alzheimer's Disease-Pipeline by Berg LLC, H2 2016 189

Alzheimer's Disease-Pipeline by BioArctic Neuroscience AB, H2 2016 190

Alzheimer's Disease-Pipeline by Bioasis Technologies Inc., H2 2016 191

Alzheimer's Disease-Pipeline by Biogen Inc, H2 2016 192

Alzheimer's Disease-Pipeline by Biomar Microbial Technologies, H2 2016 193

Alzheimer's Disease-Pipeline by Bionature E.A. Ltd., H2 2016 194

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, H2 2016 195

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Company, H2 2016 196

Alzheimer's Disease-Pipeline by Bsim2, H2 2016 197

Alzheimer's Disease-Pipeline by Cardax Pharmaceuticals, Inc., H2 2016 198

Alzheimer's Disease-Pipeline by Carna Biosciences, Inc., H2 2016 199

Alzheimer's Disease-Pipeline by Celon Pharma Sp. z o.o., H2 2016 200

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co., Ltd., H2 2016 201

Alzheimer's Disease-Pipeline by Chase Pharmaceuticals Corporation, H2 2016 202

Alzheimer's Disease-Pipeline by Clera Inc., H2 2016 203

Alzheimer's Disease-Pipeline by Cognition Therapeutics, Inc., H2 2016 204

Alzheimer's Disease-Pipeline by Cognosci, Inc., H2 2016 205

Alzheimer's Disease-Pipeline by CohBar, Inc., H2 2016 206

Alzheimer's Disease-Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 207

Alzheimer's Disease-Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 208

Alzheimer's Disease-Pipeline by Corium International, Inc., H2 2016 209

Alzheimer's Disease-Pipeline by Coronis Partners Ltd., H2 2016 210

Alzheimer's Disease-Pipeline by Cortice Biosciences, Inc., H2 2016 211

Alzheimer's Disease-Pipeline by Critical Outcome Technologies Inc., H2 2016 212

Alzheimer's Disease-Pipeline by Crossbeta Biosciences B.V., H2 2016 213

Alzheimer's Disease-Pipeline by D-Pharm Ltd., H2 2016 214

Alzheimer's Disease-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 215

Alzheimer's Disease-Pipeline by Daiichi Sankyo Company, Limited, H2 2016 216

Alzheimer's Disease-Pipeline by Daval International Limited, H2 2016 217

Alzheimer's Disease-Pipeline by DermaXon, LLC, H2 2016 218

Alzheimer's Disease-Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 219

Alzheimer's Disease-Pipeline by Eisai Co., Ltd., H2 2016 220

Alzheimer's Disease-Pipeline by Eli Lilly and Company, H2 2016 221

Alzheimer's Disease-Pipeline by Emergent BioSolutions Inc., H2 2016 222

Alzheimer's Disease-Pipeline by EncephRx, Inc., H2 2016 223

Alzheimer's Disease-Pipeline by Endece, LLC, H2 2016 224

Alzheimer's Disease-Pipeline by ENKAM Pharmaceuticals A/S, H2 2016 225

Alzheimer's Disease-Pipeline by Ensemble Therapeutics Corporation, H2 2016 226

Alzheimer's Disease-Pipeline by Ensol Biosciences Inc., H2 2016 227

Alzheimer's Disease-Pipeline by Epigen Biosciences, Inc., H2 2016 228

Alzheimer's Disease-Pipeline by Euroscreen S.A., H2 2016 229

Alzheimer's Disease-Pipeline by Evotec AG, H2 2016 230

Alzheimer's Disease-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 231

Alzheimer's Disease-Pipeline by FORUM Pharmaceuticals Inc., H2 2016 232

Alzheimer's Disease-Pipeline by Genentech, Inc., H2 2016 233

Alzheimer's Disease-Pipeline by Genervon Biopharmaceuticals, LLC, H2 2016 234

Alzheimer's Disease-Pipeline by GlaxoSmithKline Plc, H2 2016 235

Alzheimer's Disease-Pipeline by GliaCure Inc., H2 2016 236

Alzheimer's Disease-Pipeline by Glialogix, Inc., H2 2016 237

Alzheimer's Disease-Pipeline by Golden Biotechnology Corp., H2 2016 238

Alzheimer's Disease-Pipeline by Grifols, S.A., H2 2016 239

Alzheimer's Disease-Pipeline by H. Lundbeck A/S, H2 2016 240

Alzheimer's Disease-Pipeline by Heptares Therapeutics Limited, H2 2016 241

Alzheimer's Disease-Pipeline by HitGen LTD, H2 2016 242

Alzheimer's Disease-Pipeline by Humanetics Corporation, H2 2016 243

Alzheimer's Disease-Pipeline by Ichor Medical Systems, Inc., H2 2016 244

Alzheimer's Disease-Pipeline by Icure Pharmaceutical Inc., H2 2016 245

Alzheimer's Disease-Pipeline by Immungenetics AG, H2 2016 246

Alzheimer's Disease-Pipeline by Impel NeuroPharma, Inc., H2 2016 247

Alzheimer's Disease-Pipeline by ImStar Therapeutics Inc., H2 2016 248

Alzheimer's Disease-Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 249

Alzheimer's Disease-Pipeline by IntelGenx Corp., H2 2016 250

List of Figures

Number of Products under Development for Alzheimer's Disease, H2 2016 76

Number of Products under Development for Alzheimer's Disease-Comparative Analysis, H2 2016 77

Number of Products under Development by Companies, H2 2016 78

Number of Products under Investigation by Universities/Institutes, H2 2016 99

Comparative Analysis by Late Stage Development, H2 2016 106

Comparative Analysis by Clinical Stage Development, H2 2016 107

Comparative Analysis by Early Stage Products, H2 2016 108

Assessment by Monotherapy Products, H2 2016 378

Assessment by Combination Products, H2 2016 379

Number of Products by Top 10 Targets, H2 2016 380

Number of Products by Stage and Top 10 Targets, H2 2016 380

Number of Products by Top 10 Mechanism of Actions, H2 2016 404

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 404

Number of Products by Top 10 Routes of Administration, H2 2016 430

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 430

Number of Products by Top 10 Molecule Types, H2 2016 432

Number of Products by Stage and Top 10 Molecule Types, H2 2016 432

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

lzheimer's Disease-Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc

AC Immune SA

Accera, Inc.

Acelot, Inc.

Actinogen Limited

Acumen Pharmaceuticals, Inc.

Addex Therapeutics Ltd

Affibody AB

AFFiRiS AG

Alector LLC

Alkermes Plc

Allergan Plc

Allinky Biopharma

ALSP, Inc.

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings, Inc.

Amgen Inc.

Anavex Life Sciences Corp.

Aphios Corporation

Apodemus AB

Applied Research using OMIC Sciences, S.L.

Araclon Biotech, S.L.

Archer Pharmaceuticals, Inc.

ArmaGen Inc.

Artery Therapeutics, Inc.

AskAt Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Asubio Pharma Co., Ltd.

Ausio Pharmaceuticals, LLC

Avineuro Pharmaceuticals, Inc.

Axon Neuroscience SE

Axovant Sciences Ltd.

Axsome Therapeutics, Inc.

Axxam SpA

Beactica AB

Berg LLC

BioArctic Neuroscience AB

Bioasis Technologies Inc.

Biogen Inc

Biomar Microbial Technologies

Bionature E.A. Ltd.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Bsim2

Cardax Pharmaceuticals, Inc.

Carna Biosciences, Inc.

Celon Pharma Sp. z o.o.

CHA Bio & Diostech Co., Ltd.

Chase Pharmaceuticals Corporation

Clera Inc.

Cognition Therapeutics, Inc.

Cognosci, Inc.

CohBar, Inc.

Connexios Life Sciences Pvt. Ltd.

ContraVir Pharmaceuticals, Inc.

Corium International, Inc.

Coronis Partners Ltd.

Cortice Biosciences, Inc.

Critical Outcome Technologies Inc.

Crossbeta Biosciences B.V.

D-Pharm Ltd.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Daval International Limited

DermaXon, LLC

Dongkook Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

Eli Lilly and Company

Emergent BioSolutions Inc.

EncephRx, Inc.

Endece, LLC

ENKAM Pharmaceuticals A/S

Ensemble Therapeutics Corporation

Ensol Biosciences Inc.

Epigen Biosciences, Inc.

Euroscreen S.A.

Evotec AG

F. Hoffmann-La Roche Ltd.

FORUM Pharmaceuticals Inc.

Genentech, Inc.

Genervon Biopharmaceuticals, LLC

GlaxoSmithKline Plc

GliaCure Inc.

Glialogix, Inc.

Golden Biotechnology Corp.

Grifols, S.A.

H. Lundbeck A/S

Heptares Therapeutics Limited

HitGen LTD

Humanetics Corporation

Ichor Medical Systems, Inc.

Icure Pharmaceutical Inc.

Immungenetics AG

Impel NeuroPharma, Inc.

ImStar Therapeutics Inc.

Inovio Pharmaceuticals, Inc.

IntelGenx Corp.

Intellect Neurosciences, Inc.

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

Io Therapeutics, Inc.

Iproteos S.L.

Jeil Pharmaceutical Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Johnson & Johnson

K-Stemcell Co., Ltd.

Kadmon Corporation, LLC

Kalgene Pharmaceuticals Inc.

Kareus Therapeutics, SA

KineMed, Inc.

Krenitsky Pharmaceuticals Inc.

Kyowa Hakko Kirin Co., Ltd.

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Limited

Lupin Limited

M3 Biotechnology, Inc.

ManRos Therapeutics

MedDay SA

Medestea Research & Production S.p.A.

MedImmune, LLC

Medisyn Technologies, Inc.

MEDRx Co., Ltd.

Merck & Co., Inc.

Metabolic Solutions Development Company, LLC

Mithridion, Inc.

Mitochon Pharmaceuticals, Inc.

NAL Pharmaceuticals Ltd.

Nanomerics Ltd

Nanotherapeutics, Inc.

Neuralstem, Inc.

Neuraltus Pharmaceuticals, Inc.

Neurim Pharmaceuticals Ltd

Neuro-Sys SAS

Neurodyn Inc.

NeuroGeneration, Inc.

NeuroGenetic Pharmaceuticals, Inc.

NeuroNascent, Inc.

Neuronax SAS

NeurOp, Inc

NeuroPhage Pharmaceuticals, Inc.

Neuropore Therapies, Inc.

Neurotez, Inc.

New World Laboratories, Inc.

nLife Therapeutics, S.L.

NLS Pharma Group

Novartis AG

NsGene A/S

Oligomerix, inc.

ORPHIT

Oryzon Genomics SA

Otsuka Holdings Co., Ltd.

P2D Bioscience

Pain Therapeutics, Inc.

Palumed S.A.

Panacea Pharmaceuticals, Inc.

PeptiDream Inc.

Peptron, Inc.

Pfizer Inc.

PharmaKure Limited

PharmatrophiX, Inc.

Pharmaxis Limited

Pharnext SA

Phenomenome Discoveries, Inc.

Pivot Pharmaceuticals Inc

Prevacus, Inc.

Probiodrug AG

Progenra, Inc.

ProMIS Neurosciences Inc.

ProQR Therapeutics N.V.

Proteome Sciences Plc

Proteostasis Therapeutics, Inc.

QR Pharma, Inc.

Radius Health, Inc.

Regenera Pharma Ltd.

reMYND NV

Resverlogix Corp.

Retrotope, Inc

ReXceptor Inc.

Rodos BioTarget GmbH

Sage Therapeutics, Inc.

SanBio, Inc.

Saneron CCEL Therapeutics, Inc.

Saniona AB

Sanofi

Selvita S.A.

SeneXta Therapeutics SA

Serometrix, LLC

SignPath Pharma Inc

Signum Biosciences, Inc.

Simcere Pharmaceutical Group

SK Biopharmaceuticals Co., Ltd.

SOM Innovation Biotech SL

Spectrum Pharmaceuticals, Inc.

Stemedica Cell Technologies, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Summit Therapeutics Plc

Suven Life Sciences Ltd.

T3D Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

TauRx Therapeutics Ltd.

TechnologieAllianz e. V.

TechnoPhage SA

Teijin Pharma Limited

Teikoku Pharma USA, Inc.

Tetra Discovery Partners LLC

Thera Neuropharma Inc

Therapix Biosciences Ltd

Tiziana Life Sciences Plc

Toyama Chemical Co., Ltd.

Transition Therapeutics Inc.

Treventis Corporation

TyrNovo Ltd.

UCB S.A.

Varinel, Inc.

Vaxine Pty Ltd

Virobay Inc.

Vitae Pharmaceuticals, Inc.

Voyager Therapeutics, Inc.

vTv Therapeutics Inc

Vybion, Inc.

Wellstat Therapeutics Corporation

Zhejiang Hisun Pharmaceutical Co., Ltd.

Alzheimer's Disease Therapeutic Products under Development, Key Players in Alzheimer's Disease Therapeutics, Alzheimer's Disease Pipeline Overview, Alzheimer's Disease Pipeline, Alzheimer's Disease Pipeline Assessment

select a license
Single User License
USD 2500 INR 181375
Site License
USD 5000 INR 362750
Corporate User License
USD 7500 INR 544125

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com